Heron Inc

HRTX NASDAQ
17.18
+0.28
+1.66%
After Hours: 17.18 0 0.00% 17:58 08/16 EDT
Open
16.99
Prev Close
16.90
High
17.29
Low
16.76
Volume
696.23K
Avg Vol (3M)
787.25K
52 Week High
41.10
52 Week Low
15.68
% Turnover
0.87%
Market Cap
1.37B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Heron Inc HRTX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
MORE >

Recently

Name
Price
%Change